← Leaderboards
Daniel J Kass
Columbia University Health Sciences
$5,327,105
Attributed
$9,977,611
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,977,611 · 7
By mechanism
R01$5,364,998 · 3
U01$3,931,433 · 2
K08$648,540 · 1
R13$32,640 · 1
Top collaborators
- Steven R Duncan10 shared
- Gerard J Criner5 shared
- Ivan O. Rosas5 shared
- Robert A Lafyatis1 shared
- John F Mcdyer1 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Samuel Charles Silverstein$9,506,634
- Leonard Chess$400,334
- David J. Lederer$7,615,272
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungLung DiseasesPathologicPulmonary FibrosisLeadHamman-Rich SyndromePathogenesisFibrosisLung TransplantationFibroblastsMediatingGenesCellsCicatrixMyofibroblastResistanceSpecimenCollagenBleomycinIn VitroBiological MarkersCessation Of LifeKnock-OutPeptide Hydrolases
Grant awards (23)
E-Box Accessibility in Myofibroblasts in Pulmonary Fibrosis$773,440
R01 · FY2025 · HL · contact PI
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis$700,683
U01 · FY2021 · HL
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis$753,012
U01 · FY2020 · HL
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis$771,021
U01 · FY2019 · HL
Twist1 subphenotypes and pulmonary fibrosis$385,000
R01 · FY2019 · HL · contact PI
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis$771,021
U01 · FY2018 · HL
Rituximab Therapy in Patients with IPF$673,150
R01 · FY2018 · HL
Twist1 subphenotypes and pulmonary fibrosis$385,000
R01 · FY2018 · HL · contact PI
University of Pittsburgh International Lung Conference 2018--Pulmonary Medicine: Basic Biologies and Novel Therapeutics$32,640
R13 · FY2018 · HL · contact PI
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis$787,346
U01 · FY2017 · HL
Rituximab Therapy in Patients with IPF$682,198
R01 · FY2017 · HL
Twist1 subphenotypes and pulmonary fibrosis$385,000
R01 · FY2017 · HL · contact PI
Rituximab Therapy in Patients with IPF$673,599
R01 · FY2016 · HL
Twist1 subphenotypes and pulmonary fibrosis$385,000
R01 · FY2016 · HL · contact PI
Twist1 subphenotypes and pulmonary fibrosis$379,600
R01 · FY2015 · HL · contact PI
Rituximab Therapy in Patients with IPF$643,011
R01 · FY2014 · HL
Impact of CCR5 inhibition on Sarcoid Immunophenotypes$148,350
U01 · FY2014 · HL · contact PI
Methionine Aminopeptidase 2 in Pulmonary Fibrosis$129,708
K08 · FY2012 · HL · contact PI
Methionine Aminopeptidase 2 in Pulmonary Fibrosis$129,708
K08 · FY2011 · HL · contact PI
Methionine Aminopeptidase 2 in Pulmonary Fibrosis$80,000
K08 · FY2010 · HL · contact PI
Methionine Aminopeptidase 2 in Pulmonary Fibrosis$49,708
K08 · FY2010 · HL · contact PI
Methionine Aminopeptidase 2 in Pulmonary Fibrosis$129,708
K08 · FY2009 · HL · contact PI
Methionine Aminopeptidase 2 in Pulmonary Fibrosis$129,708
K08 · FY2008 · HL · contact PI